Puma Biotechnology Inc (PBYI.N)

PBYI.N on New York Stock Exchange

236.11USD
31 Mar 2015
Change (% chg)

$-3.65 (-1.52%)
Prev Close
$239.76
Open
$237.14
Day's High
$238.46
Day's Low
$234.00
Volume
130,200
Avg. Vol
40,091
52-wk High
$278.50
52-wk Low
$53.80

PBYI.N

Chart for PBYI.N

About

Puma Biotechnology, Inc. is a development-stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then... (more)

Overall

Beta: --
Market Cap(Mil.): $7,536.45
Shares Outstanding(Mil.): 31.92
Dividend: --
Yield (%): --

Financials

Search Stocks

UPDATE 1-Puma names Rihanna as women's creative director

* Puma spending on marketing to catch up with Nike, Adidas

16 Dec 2014

Puma Biotech says cancer drug fails mid-stage study

- Puma Biotechnology Inc said its cancer drug failed as a primary treatment for breast cancer patients in a mid-stage study, sending its shares down 14 percent in extended trading.

14 Nov 2014

UPDATE 1-Puma Biotech says cancer drug fails mid-stage study

Nov 13 - Puma Biotechnology Inc said its cancer drug failed as a primary treatment for breast cancer patients in a mid-stage study, sending its shares down 14 percent in extended trading.

14 Nov 2014

Puma Biotech says cancer drug fails mid-stage study

Nov 13 - Puma Biotechnology Inc said its experimental breast cancer drug failed in a mid-stage study, sending its shares down 14 percent in extended trading.

14 Nov 2014

Healthcare sector sees silver lining in U.S. tax inversion rules

NEW YORK - Investors and bankers have been lamenting the potential death of large cross-border healthcare mergers since the U.S. Treasury Department announced in late September that it would curtail the tax breaks from international deals designed to give U.S. companies a legal home in a low-tax country.

07 Nov 2014

DEALTALK-Healthcare sector sees silver lining in U.S. tax inversion rules

NEW YORK, Nov 6 - Investors and bankers have been lamenting the potential death of large cross-border healthcare mergers since the U.S. Treasury Department announced in late September that it would curtail the tax breaks from international deals designed to give U.S. companies a legal home in a low-tax country.

07 Nov 2014

Earnings vs. Estimates

Search Stocks